高级检索
当前位置: 首页 > 详情页

MEAI: an artificial intelligence platform for predicting distant and lymph node metastases directly from primary breast cancer

文献详情

资源类型:
Pubmed体系:
机构: [1]School of Artificial Intelligence and Computer Science, Jiangnan University, Wuxi, Jiangsu, China [2]Department of Vascular Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China [3]Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China [4]MOE Frontier Science Centre for Precision Oncology, University of Macau, Macau SAR, China [5]Department of Nuclear Medicine, PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China [6]Institute of Biomedical Engineering and Instrumentation, Hangzhou Dianzi University, Hangzhou, Zhejiang, China
出处:
ISSN:

摘要:
Breast cancer patients typically have decent prognoses, with a 5-year survival rate of more than 90%, but when the disease metastases to lymph node or distant, the prognosis drastically declines. Therefore, it is essential for future treatment and patient survival to quickly and accurately identify tumor metastasis in patients. An artificial intelligence system was developed to recognize lymph node and distant tumor metastases on whole-slide images (WSIs) of primary breast cancer.In this study, a total of 832 WSIs from 520 patients without tumor metastases and 312 patients with breast cancer metastases (including lymph node, bone, lung, liver, and other) were gathered. Based on the WSIs were randomly divided into the training and testing cohorts, a brand-new artificial intelligence system called MEAI was built to identify lymph node and distant metastases in primary breast cancer.The final AI system attained an area under the receiver operating characteristic curve of 0.934 in a test set of 187 patients. In addition, the potential for AI system to increase the precision, consistency, and effectiveness of tumor metastasis detection in patients with breast cancer was highlighted by the AI's achievement of an AUROC higher than the average of six board-certified pathologists (AUROC 0.811) in a retrospective pathologist evaluation.The proposed MEAI system can provide a non-invasive approach to assess the metastatic probability of patients with primary breast cancer.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]School of Artificial Intelligence and Computer Science, Jiangnan University, Wuxi, Jiangsu, China
通讯作者:
通讯机构: [1]School of Artificial Intelligence and Computer Science, Jiangnan University, Wuxi, Jiangsu, China [3]Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China [4]MOE Frontier Science Centre for Precision Oncology, University of Macau, Macau SAR, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52808 今日访问量:0 总访问量:4561 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号